Displaying 1–25 of 4051 results for
top stories in pharma manufacturing
Japan's Shionogi announced the U.S. FDA has approved its new antibiotic, Fetroja, for the treatment of complicated urinary tract infections (cUTI).
Teva Pharmaceuticals announced that it will resume production of childhood cancer drug vincristine after a recent shortage.
The FDA sent a Mylan facility in India a warning letting for its manufacturing of APIs related to the widespread recall of blood pressure medications.
Heparin, one of the world’s most critical heart medications, could soon run in short supply due to an outbreak of African swine fever that’s wiped out nearly a quarter of the world’s pigs.
AstraZeneca reported positive results this week from a late-stage lupus study.
Lonza investors were reportedly taken aback this week by the surprise announcement that the company’s CEO is planning to step down.
The company's subsidiary Nanomi B.V. will divest its entire 99.82% stake to private equity fund Unison, which has experience in the healthcare sector.
According to the Novartis subsidiary, this acquisition reinforces its strategy to focus on Japan.
The third time was not the charm for Lipocine’s male sex hormone treatment.
Positive trial results for an oral drug to treat spinal muscular atrophy (SMA) are bringing Roche one step closer to breaking into the high-cost treatment area.
The deal, originally announced back in September 2018, will not be closed until February 2020 at the earliest.
A U.S. bankruptcy judge will approve an order that will extend a stay on more than 2,600 lawsuits that accuse the company and its owners of fueling the opioid crisis.
The British drugmaker is launching a fund with China International Capital Corporation and will also begin distributing Sun Pharma cancer drugs in China.
The German Stada will acquire a portfolio of approximately 20 selected OTC and prescription pharmaceutical products in Russia, Georgia and CIS countries.
Since all the hoopla surrounding ranitidine began, the FDA has been cautious in giving a final word on how dangerous the levels of NDMA in the drug could be.
The drugmaker's biosimilar Ziextenzo hopes to help cancer patients boost infection-fighting white blood cells during chemotherapy.
The site expansion in Inchinnan, which aims to add large-volume liquid manufacturing capacity for cell culture media, is expected to be completed by June 2021
China’s regulatory authority has approved a new treatment for Alzheimer’s based on seaweed.
Johnson & Johnson said that new testing of the recently recalled batch of baby powder did not show any traces of asbestos.
President Trump formally announced his intention to nominate Dr. Stephen M. Hahn, a top executive at The University of Texas M.D. Anderson Cancer Center, to be the next commissioner of the U.S. FDA.
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug, Cosentyx, can beat the world's best-selling drug Humira in treating arthritis.
pharma manufacturing news in review
Sanofi has agreed to a $315 million payout in an aging lawsuit alleging that the drugmaker failed to use "diligent efforts" to advance development of a former Genezyme multiple sclerosis drug that would have resulted in payouts to shareholders.